5 ms·
>first time the FDA has said lifespan extension is an acceptable endpoint for a therapeutic! Oncology would like a word...(where lifespan extension is the expe
by s1artibartfast 3y ago
>first time the FDA has said lifespan extension is an acceptable endpoint for a therapeutic!
Oncology would like a word...(where lifespan extension is the expected endpoint)
If anything, the shock point is that the FDA allowed the claim without lifespan as a study endpoint/outcome, using only proxy measures.
I certainly hope someone does a follow up study to see if or how much lifespan is actually extended.
- radicaldreamer 3y agoThe reason is that this is an animal medicine so the study endpoints are much more lax than would be allowed for a medicine targeting a human indication.
- s1artibartfast 3y agoPerhaps, there have been a few recent human approvals based solely on proxy endpoints as well. Imo, all such studies, human or animal should require large post approval RCTs